Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2010 1
2012 1
2013 3
2014 2
2015 1
2017 1
2018 2
2019 1
2020 3
2021 2
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial.
Charles P, Perrodeau É, Samson M, Bonnotte B, Néel A, Agard C, Huart A, Karras A, Lifermann F, Godmer P, Cohen P, Hanrotel-Saliou C, Martin-Silva N, Pugnet G, Maurier F, Sibilia J, Carron PL, Gobert P, Meaux-Ruault N, Le Gallou T, Vinzio S, Viallard JF, Hachulla E, Vinter C, Puéchal X, Terrier B, Ravaud P, Mouthon L, Guillevin L; French Vasculitis Study Group. Charles P, et al. Among authors: godmer p. Ann Intern Med. 2020 Aug 4;173(3):179-187. doi: 10.7326/M19-3827. Epub 2020 Jun 2. Ann Intern Med. 2020. PMID: 32479166 Clinical Trial.
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort.
Comarmond C, Pagnoux C, Khellaf M, Cordier JF, Hamidou M, Viallard JF, Maurier F, Jouneau S, Bienvenu B, Puéchal X, Aumaître O, Le Guenno G, Le Quellec A, Cevallos R, Fain O, Godeau B, Seror R, Dunogué B, Mahr A, Guilpain P, Cohen P, Aouba A, Mouthon L, Guillevin L; French Vasculitis Study Group. Comarmond C, et al. Arthritis Rheum. 2013 Jan;65(1):270-81. doi: 10.1002/art.37721. Arthritis Rheum. 2013. PMID: 23044708 Free article.
This study was undertaken to describe the main characteristics of a larger patient cohort and their long-term outcomes. METHODS: A retrospective study of EGPA patients in the French Vasculitis Study Group cohort who satisfied the American College of Rheumatology criteria a …
This study was undertaken to describe the main characteristics of a larger patient cohort and their long-term outcomes. METHODS: A re …
Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials.
Delestre F, Charles P, Karras A, Pagnoux C, Néel A, Cohen P, Aumaître O, Faguer S, Gobert P, Maurier F, Samson M, Godmer P, Bonnotte B, Cottin V, Hanrotel-Saliou C, Le Gallou T, Carron PL, Desmurs-Clavel H, Direz G, Jourde-Chiche N, Lifermann F, Martin-Silva N, Pugnet G, Quéméneur T, Matignon M, Benhamou Y, Daugas E, Lazaro E, Limal N, Ducret M, Huart A, Viallard JF, Hachulla E, Perrodeau E, Puechal X, Guillevin L, Porcher R, Terrier B; French Vasculitis Study Group (FVSG). Delestre F, et al. Among authors: godmer p. Ann Rheum Dis. 2024 Jan 11;83(2):233-241. doi: 10.1136/ard-2023-224623. Ann Rheum Dis. 2024. PMID: 37918894
OBJECTIVE: To compare the long-term efficacy and safety of azathioprine (AZA), 18-month fixed-schedule rituximab (RTX), 18-month tailored RTX and 36-month RTX in preventing relapses in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis who achie …
OBJECTIVE: To compare the long-term efficacy and safety of azathioprine (AZA), 18-month fixed-schedule rituximab (RTX), 18-month tail …
Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Terrier B, Pagnoux C, Perrodeau É, Karras A, Khouatra C, Aumaître O, Cohen P, Decaux O, Desmurs-Clavel H, Maurier F, Gobert P, Quémeneur T, Blanchard-Delaunay C, Bonnotte B, Carron PL, Daugas E, Ducret M, Godmer P, Hamidou M, Lidove O, Limal N, Puéchal X, Mouthon L, Ravaud P, Guillevin L; French Vasculitis Study Group. Terrier B, et al. Among authors: godmer p. Ann Rheum Dis. 2018 Aug;77(8):1150-1156. doi: 10.1136/annrheumdis-2017-212768. Epub 2018 May 3. Ann Rheum Dis. 2018. PMID: 29724729 Clinical Trial.
OBJECTIVE: To compare long-term efficacy of remission-maintenance regimens in patients with newly diagnosed or relapsing antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitides. ...
OBJECTIVE: To compare long-term efficacy of remission-maintenance regimens in patients with newly diagnosed or relapsing antineutroph …
Deleterious neurological impact of diagnostic delay in immune-mediated thrombotic thrombocytopenic purpura.
Renaud A, Caristan A, Seguin A, Agard C, Blonz G, Canet E, Eveillard M, Godmer P, Graveleau J, Lecouffe-Desprets M, Maisonneuve H, Perrin F, Hamidou M, Néel A. Renaud A, et al. Among authors: godmer p. PLoS One. 2021 Nov 19;16(11):e0260196. doi: 10.1371/journal.pone.0260196. eCollection 2021. PLoS One. 2021. PMID: 34797873 Free PMC article.
However, the exact impact of a slight delay in TPE initiation on the subsequent patients' outcome is still controversial. AIM: We aimed to study the frequency, short-term neurological consequences, and determinants of diagnostic delay in iTTP. ...CONCLUSION: Diagnostic del …
However, the exact impact of a slight delay in TPE initiation on the subsequent patients' outcome is still controversial. AIM: We aimed to s …
Granulomatosis with polyangiitis: Study of 795 patients from the French Vasculitis Study Group registry.
Iudici M, Pagnoux C, Courvoisier DS, Cohen P, Hamidou M, Aouba A, Lifermann F, Ruivard M, Aumaître O, Bonnotte B, Maurier F, Decaux O, Hachulla E, Karras A, Khouatra C, Jourde-Chiche N, Viallard JF, Blanchard-Delaunay C, Godmer P, Quellec AL, Quéméneur T, de Moreuil C, Régent A, Terrier B, Mouthon L, Guillevin L, Puéchal X; French Vasculitis Study Group. Iudici M, et al. Among authors: godmer p. Semin Arthritis Rheum. 2021 Apr;51(2):339-346. doi: 10.1016/j.semarthrit.2021.02.002. Epub 2021 Feb 10. Semin Arthritis Rheum. 2021. PMID: 33601189
OBJECTIVE: To describe the characteristics and long-term outcomes of patients with granulomatosis with polyangiitis (GPA) from the French Vasculitis Study Group database. ...
OBJECTIVE: To describe the characteristics and long-term outcomes of patients with granulomatosis with polyangiitis (GPA) from the Fr …
Localized versus systemic granulomatosis with polyangiitis: data from the French Vasculitis Study Group Registry.
Iudici M, Pagnoux C, Courvoisier DS, Cohen P, Néel A, Aouba A, Lifermann F, Ruivard M, Aumaître O, Bonnotte B, Maurier F, Le Gallou T, Hachulla E, Karras A, Khouatra C, Jourde-Chiche N, Viallard JF, Blanchard-Delaunay C, Godmer P, Le Quellec A, Quéméneur T, de Moreuil C, Régent A, Terrier B, Mouthon L, Guillevin L, Puéchal X; French Vasculitis Study Group. Iudici M, et al. Among authors: godmer p. Rheumatology (Oxford). 2022 May 30;61(6):2464-2471. doi: 10.1093/rheumatology/keab719. Rheumatology (Oxford). 2022. PMID: 34542599
L-GPA and S-GPA patients' characteristics at diagnosis and long-term outcomes were analysed and compared. RESULTS: Among the 795 Registry patients, 79 (10%) had L-GPA. ...
L-GPA and S-GPA patients' characteristics at diagnosis and long-term outcomes were analysed and compared. RESULTS: Among the 795 Regi …
Central nervous system involvement of granulomatosis with polyangiitis: clinical-radiological presentation distinguishes different outcomes.
De Luna G, Terrier B, Kaminsky P, Le Quellec A, Maurier F, Solans R, Godmer P, Costedoat-Chalumeau N, Seror R, Charles P, Cohen P, Puéchal X, Mouthon L, Guillevin L; French Vasculitis Study Group (FVSG). De Luna G, et al. Among authors: godmer p. Rheumatology (Oxford). 2015 Mar;54(3):424-32. doi: 10.1093/rheumatology/keu336. Epub 2014 Sep 3. Rheumatology (Oxford). 2015. PMID: 25187644
Initial spinal cord pachymeningitis was significantly associated with the need for a new induction regimen for relapsing/refractory disease (P = 0.01). Long-term neurological sequelae were noted in 51% of patients, including 35% with G-CNS and 69% with V-CNS (P = 0.08). .. …
Initial spinal cord pachymeningitis was significantly associated with the need for a new induction regimen for relapsing/refractory disease …
Intravenous Immunoglobulins Improve Survival in Monoclonal Gammopathy-Associated Systemic Capillary-Leak Syndrome.
Pineton de Chambrun M, Gousseff M, Mauhin W, Lega JC, Lambert M, Rivière S, Dossier A, Ruivard M, Lhote F, Blaison G, Alric L, Agard C, Saadoun D, Graveleau J, Soubrier M, Lucchini-Lecomte MJ, Christides C, Bosseray A, Levesque H, Viallard JF, Tieulie N, Lovey PY, Le Moal S, Bibes B, Malizia G, Abgueguen P, Lifermann F, Ninet J, Hatron PY, Amoura Z; EurêClark Study Group. Pineton de Chambrun M, et al. Am J Med. 2017 Oct;130(10):1219.e19-1219.e27. doi: 10.1016/j.amjmed.2017.05.023. Epub 2017 Jun 9. Am J Med. 2017. PMID: 28602874
This study was conducted to better describe the clinical characteristics, natural history, and long-term outcome of monoclonal gammopathy-associated systemic capillary-leak syndrome. ...
This study was conducted to better describe the clinical characteristics, natural history, and long-term outcome of monoclonal gammop …
Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis.
Charles P, Dechartres A, Terrier B, Cohen P, Faguer S, Huart A, Hamidou M, Agard C, Bonnotte B, Samson M, Karras A, Jourde-Chiche N, Lifermann F, Gobert P, Hanrotel-Saliou C, Godmer P, Martin-Silva N, Pugnet G, Matignon M, Aumaitre O, Viallard JF, Maurier F, Meaux-Ruault N, Rivière S, Sibilia J, Puéchal X, Mouthon L, Guillevin L; French Vasculitis Study Group. Charles P, et al. Among authors: godmer p. Rheumatology (Oxford). 2020 Oct 1;59(10):2970-2975. doi: 10.1093/rheumatology/kez621. Rheumatology (Oxford). 2020. PMID: 32150263 Free article. Clinical Trial.
CONCLUSIONS: We were not able to detect a difference between the relapse-free survival rates for up to M12 for the D0 and D0+D14 rituximab-infusion groups, which could suggest that omitting the D14 rituximab remission-maintenance dose did not modify the short-term relapse- …
CONCLUSIONS: We were not able to detect a difference between the relapse-free survival rates for up to M12 for the D0 and D0+D14 rituximab-i …
18 results